Ignite Creation Date:
2024-05-05 @ 11:32 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00075218
Status:
COMPLETED
Last Update Posted:
2009-09-28
First Post:
2004-01-06
Brief Title:
A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal TumorGIST
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase III Randomized Double-Blind Placebo-Controlled Study Of SU011248 In The Treatment Of Patients With Imatinib Mesylate Gleevec Tm Glivec-Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor
Status:
COMPLETED
Status Verified Date:
2009-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A study to assess the safety and efficacy of SU11248 in patients with gastrointestinal stromal tumor GIST whose disease has failed imatinib therapy or who were intolerant to imatinib treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None